To determine if there are significant differences in biochemical characteristics, biopsy variables, histopathological data, and rates of prostate-specific antigen (PSA) recurrence between African-American (AA) and white American (WA) men undergoing radical prostatectomy (RP), as AA men are twice as likely to die from prostate cancer than their white counterparts.
In a multi-institutional study authors from the USA and Austria attempt to determine if there are differences in several indices between African-American and white men undergoing radical prostatectomy. They did not find race to be an independent risk factor for PSA recurrence, but found that other variables commonly associated with PSA recurrence are also important in African-Americans.
Using data extracted from the Hospital Episodes database, authors from England describe national trends in radical nephrectomy between 1995 and 2002. They found a considerable increase in the annual number of radical nephrectomies, with an expected increase in the number of laparoscopic procedures. They also found a decrease in emergency admissions and length of hospital stay.
INTRODUCTION
The number of new cases of prostate cancer was estimated at 513 000 worldwide and 173 000 in the USA, accounting for 15.3% of all cancers in men in developed countries in 2000 [1] . Within the next 15 years, prostate cancer is predicted to be the most common cancer in men [1] . The incidence of prostate cancer varies widely among ethnic populations, and the rate of this disease can differ by as much as 90 times among various populations. Specifically, African-American (AA) men in the USA have the highest incidence of prostate cancer (137 per 100 000 per year) [2] .
According to the 2000 USA Census, AAs comprise the second largest racial group in the USA; that AA men have a 2.5 times greater mortality from prostate cancer than white Americans (WA) has become a significant health concern in the USA [2] . This strikingly higher mortality for AA men raises several questions. Is the difference in mortality a result of diagnosis at later, more advanced disease stages? Or is it because prostate cancer is more biologically aggressive in AA men? [3] . It may also be possible that AA men are receiving different treatments for their prostate cancer than other populations [4] . In addition, is there a role for competing causes of death such as comorbidity and age? Finally, do poverty, socio-economic status and education have a role? [4] .
Several authors [4] [5] [6] [7] [8] [9] [10] have examined an important surrogate, PSA recurrence, as a measure of prostate cancer-specific mortality. These studies evaluated clinical and pathological variables before and after surgery, socio-economic factors, and delivery of healthcare; the results are conflicting [4] [5] [6] [7] [8] [9] [10] . Recently there has been interest in the PSA doubling time as a surrogate for the ultimate outcome of prostate cancer [11] . Differences in PSA doubling times before and after treatment among races have been studied in a few series [5] , but there is no comprehensive report of this subject in AAs in an equal-access setting. To address this issue, we evaluated differences in PSA doubling times, histopathological variables, and the incidence of PSA recurrence between AA and WA men with clinically localized prostate cancer. Accordingly, the analysis was limited to patients undergoing radical retropubic prostatectomy (RP) to ensure the availability of histopathological data from the excised surgical specimen. A univariate analysis was used to compare the pathological variables at baseline and after RP between the racial groups. Comparisons of PSA recurrence were based on survival analysis. The Cox proportional-hazards model was used for multivariate survival analysis, which allowed an estimate of the PSA recurrence time, controlling for differences in follow-up time and risk factors that may affect survival, including confounding variables and effect modifiers. All relative risks were derived from the multivariate Cox models. Adjusted survival curves were generated using the empirical cumulative hazard estimate of the survivor function. Differences in the duration of survival were calculated by measuring differences in the adjusted survival curves at median survival.
PATIENTS AND METHODS

This
All P values were two-sided.
RESULTS
The baseline characteristics of the cohort of 1058 patients are summarized in Table 1 . An important and surprising finding of the study was that at baseline, AA men had a shorter PSA doubling time than WA men ( Table 1) . 
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these data showed that there was > 3 years difference in PSA doubling time between the racial groups. None of the other study endpoints, i.e. margin positivity, seminal vesicle infiltration and lymph node spread, were statistically different between the cohorts.
As shown in Table 2 Table 2 ).
In the Cox proportional-hazard model race was not an independent predictor of PSA recurrence ( 
DISCUSSION
Overall mortality from prostate cancer is greater in AA than WA men; historically, this has been attributed to a more advanced tumour stage in AA men at diagnosis. More recently, increased awareness and the widespread use of PSA screening has dramatically increased the detection of earlier stage cancers. This has been associated with a clear improvement in mortality and survival rates, especially in AA men, where there has been an improvement of 21% in organconfined disease. Some have argued that the treatment outcome has been better in WA than AA men for localized prostate cancer, but others have argued that there is no significant racial difference in treatment outcome [4] [5] [6] [7] 9, 10, 12] .
The present study indicates that there are racial differences in baseline serum PSA, PSA doubling times, clinical and pathological stages, and the incidence of HGPIN. However, race alone did not appear to be an independent risk factor for PSA recurrence. Rather, other variables, e.g. pathology Gleason score, bilateral cancers, HGPIN and margin positivity, were independently associated with PSA recurrence. The present study is unique in that it includes a significant proportion of AA patients (38%) and has many additional variables that could affect PSA recurrence. Further, we also showed that while PSA recurrence rates are no different between AA and WA men, PSA levels double much faster in the former than the latter. The biological significance of a rapid PSA doubling time is currently unknown, but given the association of a rapid PSA doubling with earlier development of metastasis [11, 13] , it can be postulated that after PSA recurrence, AA men may have a more aggressive course of disease. This finding is in contrast with results from a detailed study by Banerjee et al. [5] , who reported that the mean average relative PSA velocity for AA and WA men having disease recurrence was 0.25 and 0.11 ng/mL per month, respectively ( P = 0.21). The rate of PSA increase in patients who developed disease recurrence after RP was 18.9% per month for AA men and 16.3% per month for WAs ( P = 0.73). The present results may differ because the follow-up was longer (78 months) than that assessed by Banerjee et al. , where the median follow-up was 39 months. The brevity of the PSA doubling time was also noted before RP in the present series, but the significance of this finding is unknown. Several studies reported that a rapid PSA doubling time may be associated with more aggressive disease [4] [5] [6] [7] 9, 10, 12] . We postulate that even though PSA recurrence rates are comparable, AA men who develop PSA recurrence may have a more accelerated course of disease. This hypothesis is currently being tested at our centre in patients for whom long-term survival data are available.
Whether race is truly predictive of PSA recurrence after RP has been controversial. Earlier reports stated that race is an independent predictor of outcome, while recently many authors reported that there is The present findings are robust because the analysis involved patients from an equalaccess system, which minimizes potential access-related issues in healthcare. Other studies [9] showed that lack of healthcare insurance and barriers to access could delay diagnosis and affect outcome. Therefore, the present study is more suitable for determining whether race is an independent factor for PSA recurrence; we conclude that race is not independently associated with PSA recurrence but must acknowledge that AA men have a shorter PSA doubling time, which may translate into more aggressive disease. Our centre is currently studying long-term data from these patients.
Another strength of the present study is that it includes several additional histopathological variables which could affect PSA recurrence. Specifically, we assessed differences in PNI, inflammation and percentage cancer in the biopsy. None of these variables was more prevalent in AA patients, but the incidence of HGPIN was significantly greater in AA men and associated with a greater incidence of PSA recurrence. An important limitation of the study is its retrospective design, but the large sample size and inclusion of several confounding variables potentially offset this limitation.
In conclusion, AA race is not an independent risk factor for PSA recurrence in patients undergoing RP, and AA men have no greater incidence of HGPIN, higher baseline PSA level, or rapid PSA doubling before RP or after recurrence. Early PSA testing and aggressive evaluation of abnormal PSA, and of HGPIN, could result in the diagnosis of early prostate cancer and ultimately prolong survival.
